This page uses content from Wikipedia and is licensed under CC BY-SA.

Basmisanil

Basmisanil
Basmisanil.svg
Clinical data
SynonymsRG-1662; RO5186582
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC21H20FN3O5S
Molar mass445.47 g·mol−1
3D model (JSmol)

Basmisanil (INN; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied.[4]

See also

References

  1. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  2. ^ Hurley, Dan (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
  3. ^ Rudolph, Uwe; Jensen, Henrik Sindal; Nichol, Kathryn; Lee, Deborah; Ebert, Bjarke (2014). "Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes". PLoS ONE. 9 (2): e88456. doi:10.1371/journal.pone.0088456. ISSN 1932-6203. PMC 3922815.
  4. ^ Marly Chevrette. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.

External links